Literature DB >> 17473381

Holistic and network analysis of meningioma pathogenesis and malignancy.

Yingqun Tao1, Qing Wei, Zaihua Xu, Rulin Bai, Yao Li, Chun Luo, Yan Dong, Guoyi Gao, Yicheng Lu.   

Abstract

Meningiomas, which originate from arachnoid cells and constitute the largest subgroup of all intracranial tumors, are generally benign, yet have the capacity to progress into a higher histological grade of malignancy associated with an increase in biological aggressivity and/or capacity to recur. To elucidate meningioma pathogenesis and malignancy, we applied a holistic and network approach analyzing cDNA and tissue microarray results. A potential pathway leading to meningioma angiogenesis, apoptosis and proliferation was evidenced as well as a regulatory network of the biomarkers including Ki-67, AR, CD34, P53, c-MYC, etc. which might support clinical research. In this potential pathway, ITGB1 could be the most important "superoncogene" playing a vital role in apoptosis and proliferation, while FOXO3A, MDM4 and MT3 are important to the malignancy process. Some genes are first reported that could explain why radiation induces meningioma and why more female than male patients are affected. Further, we present the hypothesis that HIV-Tat protein might have a close relationship with meningioma pathogenesis and malignancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17473381     DOI: 10.1002/biof.5520280307

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  2 in total

1.  Identification of Diagnostic Markers Correlated With HIV+ Immune Non-response Based on Bioinformatics Analysis.

Authors:  Ruojing Bai; Zhen Li; Yuying Hou; Shiyun Lv; Ran Wang; Wei Hua; Hao Wu; Lili Dai
Journal:  Front Mol Biosci       Date:  2021-12-22

2.  Human Immunodeficiency Virus in Adults Undergoing Surgery for Brain Tumors.

Authors:  Lauren Harris; Shahinur Rahman; Mohamed Khoudir; Hu Liang Low; Babar Vaqas
Journal:  Cureus       Date:  2022-07-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.